GlobeNewswire

TME Pharma provides further details on the exclusive negotiation agreement with TMS Co., Ltd. for NOX-A12
10/11/2026
TME Pharma provides further details on the exclusive negotiation agreement with TMS Co., Ltd. for NOX-A12 Berlin, Germany, November 10, 2026, 8.30 am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotech- [...]
TME Pharma fournit davantage de détails sur l'accord de négociation exclusif conclu avec TMS Co., Ltd. concernant le NOX-A12
10/11/2026
TME Pharma fournit davantage de détails sur l'accord de négociation exclusif conclu avec TMS Co., Ltd. concernant le NOX-A12 Berlin, Allemagne, le 10 novembre 2026, 8h30 CET – TME Pharma N.V. (Euronext Growth Paris: [...]
Trogenix appoints industry veterans John Young as Chair and Josh Murray as Non-Executive Director to support global strategy, commercial foundation and patient access
10/11/2026
John brings more than 35 years of operational and commercial leadership with extensive experience in bringing medicines to market at global scale Josh brings deep capital markets and strategic experience to support the [...]
Roche presents new data across pharmaceuticals and diagnostics from its growing Alzheimer’s disease portfolio at CTAD 2026
10/11/2026
Updated Phase Ib/IIa Brainshuttle™ AD study data for trontinemab demonstrating rapid amyloid removal dynamics and changes in key biomarkers Phase III PrevenTRON study design specifics for trontinemab in preclinical [...]
Valneva Reports Sustained 94% Seroresponse Five Years After a Single Dose of Chikungunya Vaccine IXCHIQ®
10/11/2026
94% of participants maintained seroresponse five years after a single vaccination Comparable antibody persistence observed in older (65+) and younger adults Data further reinforce IXCHIQ ® 's differentiated profile with [...]
Valneva annonce un taux de séroréponse de 94% cinq ans après une dose unique du vaccin contre le chikungunya IXCHIQ®
10/11/2026
94% des participants ont maintenu une séroréponse cinq ans après une dose unique du vaccin La persistance des anticorps chez les adultes âgés de 65 ans et plus est comparable à celle des jeunes adultes Ces données [...]
Australian therapy aimed at halting MND progression and restoring function advances to national Phase 2 trial
10/11/2026
Video interviews, overlay and photos here BRISBANE, Australia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- An Australian-developed therapy aimed at halting the progression of motor neurone disease (MND) and restoring function by [...]
Nanox Announces That Board Has Approved Cost Reduction and Operational Efficiency Measures
09/11/2026
The Board approved plan target s a 25%–30% reduction in annualized operating expenses, compared to annualized 2026 GAAP and non-GAAP operating expenses, once fully implemented, expected by the end of Q 1 202 7 Cost [...]
Five Vital Nutrients Bestsellers Earn TESTED by SuppCo Certification Verifying Label Claims
09/11/2026
MIDDLETOWN, Conn., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Vital Nutrients , a practitioner-founded nutritional supplement company, today announced that five of its dietary supplements have earned TESTED by SuppCo [...]
Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
09/11/2026
NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that in connection with the hiring, [...]
Robert Whitfield MD PLLC Marks Two Years of the SHARP Method, Drawing Surgical Patients From 40 States and Abroad
09/11/2026
First published by board-certified plastic surgeon Dr. Robert Whitfield in his book two years ago, the program pairs individualized health assessment before surgery with patient education and in-clinic recovery support [...]
Digbi Health Reports 18.4% Weight Loss With Tirzepatide, Challenges One-Size-Fits-All GLP-1 Care
09/11/2026
Real-world results from 3,181 members across 10 employers, to be presented at Obesity Week® 2026, beat every published cohort on the same drug with standard care. The difference: precision biology and AI that [...]
Mesa Labs Announces Second Quarter Fiscal Year 2027 Results and Issues First Full-Year Guidance
09/11/2026
LAKEWOOD, Colo., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of critical quality control solutions and life sciences [...]
Cellectis to Report Third Quarter Financial Results on November 12, 2026
09/11/2026
NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a genome engineering company developing genetic medicines for diseases that today demand a lifetime of [...]
Cellectis publiera ses résultats financiers du troisième trimestre le 12 novembre 2026
09/11/2026
NEW YORK, 09 nov. 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société d’ingénierie du génome qui développe des médicaments génétiques destinés à des maladies aujourd’hui traitées à vie, [...]
BioCardia to Host Q3 2026 Financial Results and Corporate Update Conference Call on November 12, 2026
09/11/2026
SUNNYVALE, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ:BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced [...]
Precision Optics Schedules First Quarter Fiscal 2027 Conference Call for November 16, 2026
09/11/2026
LITTLETON, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/ [...]
Nanobiotix to Participate in Investor Conferences in November
09/11/2026
PARIS and CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand [...]
NANOBIOTIX PARTICIPERA À PLUSIEURS CONFÉRENCES INVESTISSEURS EN NOVEMBRE
09/11/2026
PARIS et CAMBRIDGE, Mass., 09 nov. 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société » ), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum